The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2026 |
Meiyan Zhou, Xiaoyan Xue, Huifang Li, Ziqi Chen, Qihong Nie, Yongchang Lai. Decoding the metabolic-immune axis for novel therapeutics in bladder cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026; 1881: 189569189569. https://doi.org/10.1016/j.bbcan.2026.189569 |
|
2 |
2025 |
Peng Chen, Junhao Chen, Peiqin Zhan, Xinni Ye, Li Zhao, Zhongsong Zhang, Jieming Zuo, Hongjin Shi, Xiangyun Li, Songhong Wu, Yuanzhi Fu, Haifeng Wang, Shi Fu. Targeting Cancer-Associated Fibroblasts in Prostate Cancer: Recent Advances and Therapeutic Opportunities, Cancers. 2025; 18: 151. https://doi.org/10.3390/cancers18010151 |
|
3 |
2026 |
Fei Zhang, Shuai Li, Zhijie Zhang, Jiulong Li, Huiqin Liu, Xudong Ma, Zhigang Yang. Identification of DNA Replication Stress-Related Genes as Prognostic Biomarkers for Bladder Cancer, Combinatorial Chemistry & High Throughput Screening. 2026; 29: 291. https://doi.org/10.2174/0113862073396305250526102508 |
|
4 |
2025 |
Anna Di Spirito, Gaia Zuccolotto, Anna Tosi, Sahar Balkhi, Antonio Rosato, Denisa Baci, Lorenzo Mortara. Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies, Frontiers in Cell and Developmental Biology. 2025; 13: 1719978. https://doi.org/10.3389/fcell.2025.1719978 |
|
5 |
2026 |
Qiwei Nie, Minyao Jiang, Song Wan, Ming Xi, Wei Hua, Funeng Jiang, Weide Zhong. Neuro-immune–related gene signatures define molecular subtypes and prognostic score in bladder cancer with SERPINE2 as a potential therapeutic target, PeerJ. 2026; 14: e20917e20917. https://doi.org/10.7717/peerj.20917 |
|
6 |
2026 |
Kejun Qu, Yifan Zhang, Chan Qiang, Zimu Yu, Xixi Jing, Zewei Wang, Jishen Zhang, Zifeng Wang, Dingxin Liu, Hao Zhang, Xiaojian Yang, Mingzhe Rong. Plasma‐Activated Saline Triggers Macrophage M1 Polarization by Inducing Tumor Cell Apoptosis, Plasma Processes and Polymers. 2026; 23: e70132. https://doi.org/10.1002/ppap.70132 |
|
7 |
2026 |
Qinsha Wang, Haihong Wang, Peng Lan, Bing Yang, Jia Deng, Kangmin Zhou, Dongxin Tang. Integrative Transcriptomics, Machine Learning, and Molecular Dynamics Reveal Honghua Longdan (Gentiana rhodantha)-Modulated Therapeutic Targets in Bladder Cancer, ACS Omega. 2026; acsomega.5c12612. https://doi.org/10.1021/acsomega.5c12612 |
|
8 |
2025 |
Xiaoyun Wang, Siliang Chen, Gu He, Yanghui Zhu, Nan Zhang, Changyang Gong, Xiang Li, Yujuan Chen. Cholesterol modified defense peptide as an EMP2-siRNA delivery system for synergistic immunogene therapy against breast cancer, Materials Today Bio. 2025; 35: 102321102321. https://doi.org/10.1016/j.mtbio.2025.102321 |
|
9 |
2026 |
Xiaojuan Tang, Ling Liu, Min Gao, Peng Duan, Sheng Li, Zilong Yuan, Qiang Xia, Lei Xi, Yan Tan. Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer, Scientific Reports. 2026; 16: 7151. https://doi.org/10.1038/s41598-026-38219-x |
|
10 |
2025 |
Sahar Balkhi, Anna Di Spirito, Lorenzo Mortara. Innate Priming and Tumor-Associated Macrophage Reprogramming: A Commentary on Emerging Immunotherapeutic Strategies, Frontiers in Bioscience-Landmark. 2025; 30: 41097. https://doi.org/10.31083/FBL41097 |
|
11 |
2025 |
Ming-Cheng Chang, Wan-Chi Lee, Yi-Jou Tai, Ying-Cheng Chiang. BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy, Pharmaceuticals. 2025; 18: 1784. https://doi.org/10.3390/ph18121784 |
|
12 |
2026 |
Kun Zhao, Zhongze Zhou, Xueming Ma, Xi Xiao, Long Cheng, Shuai Liu, Wenyun Wang, Zhilong Dong. Progress and challenges in CAR-T cell therapy for bladder cancer, Critical Reviews in Oncology/Hematology. 2026; 222: 105275105275. https://doi.org/10.1016/j.critrevonc.2026.105275 |
|
13 |
2026 |
民健 江, HER2 in Non-Muscle-Invasive Bladder Cancer: A Comprehensive Review of Diagnosis, Prognosis, and Targeted Therapy, Advances in Clinical Medicine. 2026; 16: 1314. https://doi.org/10.12677/acm.2026.162517 |
|
14 |
2026 |
Lichen Zhou, Wenjie Zhang, Zhuoran Liu, Yaming Xie, Kangyi Jiang. Immune cell metabolic reprogramming in hepatocellular carcinoma: mechanisms, tumor microenvironment, and future immunotherapeutic directions, Frontiers in Immunology. 2026; 16: 1697675. https://doi.org/10.3389/fimmu.2025.1697675 |